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Abstract: Omega-3 fatty acids, specifically eicosapentanoic acid (EPA, 20:5n-3) and docosahexanoic
acid (DHA, 22:6n-3) are receiving increasing attention in sports nutrition. While the usual focus
is that of athletes, questions remain if the different training status between athletes and amateurs
influences the response to EPA/DHA, and as to whether amateurs would benefit from EPA/DHA
supplementation. We critically examine the efficacy of EPA/DHA on performance, recovery and
injury/reduced risk of illness in athletes as well as amateurs. Relevant studies conducted in amateurs
will not only broaden the body of evidence but shed more light on the effects of EPA/DHA in
professionally trained vs. amateur populations. Overall, studies of EPA/DHA supplementation in
sport performance are few and research designs rather diverse. Several studies suggest a potentially
beneficial effect of EPA/DHA on performance by improved endurance capacity and delayed onset
of muscle soreness, as well as on markers related to enhanced recovery and immune modulation.
The majority of these studies are conducted in amateurs. While the evidence seems to broadly
support beneficial effects of EPA/DHA supplementation for athletes and more so in amateurs, strong
conclusions and clear recommendations about the use of EPA/DHA supplementation are currently
hampered by inconsistent translation into clinical endpoints.
Keywords: omega-3 fatty acids; sports nutrition; athletes; amateurs; performance; recovery; injury
1. Introduction
The main purpose of nutrition for athletes is to compensate for increased energy and nutrient
needs. In recent years, the role of omega-3 fatty acids in sport has received increasing research
attention [1]. Omega-3 fatty acids are perceived as a potential supplement that may beneficially affect
performance, recovery and the risk for illness/injury [2]. Omega-3 fatty acids belong to the family
of polyunsaturated fatty acids [3]. While there are fatty acids of varying length, the most important
ones are considered to be the very long-chain fatty acids eicosapentanoic acid (EPA, 20:5n-3) and
docosahexanoic acid (DHA, 22:6n-3) [4]. The predominant source for EPA/DHA is seafood, particularly
fatty fish, such as mackerel and herring. Although food items such as linseed oil and walnut oil have
high amounts of the plant-derived omega-3 fatty acid α-linolenic acid (ALA, 18:3n-3) they are not
routinely consumed in large quantities. Other food products, such as soybeans, squash and wheat
germ cereals contain less ALA but are often consumed in higher amounts and therefore contribute
significantly to ALA intake. While EPA can be synthesized from ALA, the conversion of ALA to
EPA and further to DHA is characterized by a low conversion rate [5], therefore the consumption
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of EPA/DHA via seafood is generally recommended. Although the current recommendations stand,
it should be noted that there is a substantial genetic variation in the fatty acid metabolism [6].
In the European Union (EU), across all populations, EPA and DHA intake is not adequate; in 74%
of the EU countries the intake was found to be lower than the European Food Safety Agency (EFSA)
recommendation of 250 mg for EPA and DHA as adequate intake for adults based on cardiovascular
considerations [7,8]. The current dietary guidelines for Americans suggest the same value [9]. EPA/DHA
are considered safe up to 5 g per day [10]. Although EFSA’s recommendation is for the normal, healthy
population, it is reasonable to assume that neither athletes nor amateurs consume adequate amounts
either considering their higher energy turnover and metabolic flux. In fact, analyses of dietary habits
in various athletes found that substantial proportions of the studied populations did not reach the
dietary goals for macro- and micronutrients, including EPA/DHA [11,12]. Furthermore, a recent
multi-center, cross-sectional study in 404 National Collegiate Athletic Association Division I football
athletes revealed that no athlete had an Omega-3 Index associated with low risk [13].
While there are some data that EPA/DHA may improve endurance capacity and promote recovery
in athletic populations [14], current evidence lacks consensus [1]. Given the fact that a lot of studies
with omega-3 fatty acids were conducted in non-professionals, we also include studies conducted
in amateurs (defined as people pursuing an activity for pleasure without payment and not as a
job). Broadening the data base may shed more light on the effects of EPA/DHA supplementation on
performance parameters. Furthermore, this large section of the population is also of interest as it can
potentially benefit from an optimized diet as well. Studies were included when parameters relevant for
performance, recovery and risk of illness/injury were reported. Hence, this narrative review identifies
relevant human intervention studies and evaluates the overall impact of EPA/DHA in sport nutrition
for athletes as well as amateurs. The scope of this review is to provide a simplified and exploratory, yet
relevant approach to assess the role of EPA/DHA on outcomes related to performance, recovery and
illness/injury in two different populations, athletic as well as amateurs, by using dichotomous splits to
describe the study outcomes focusing on study duration and dose. The differentiation between athletes
and amateurs is important, because the metabolic state, i.e., training status may well influence the
response to a given stimulus or supplementation. In general, varying designs particularly in the dose of
EPA/DHA as well as the duration of supplementation contribute substantially to the partly inconsistent
outcomes. Our approach enabled us to identify differences in outcomes related to dose and duration
between athletes and amateurs, which may translate not only into tailored intake recommendations but
into design considerations for future clinical trials to assess the efficacy of EPA/DHA supplementation
in performance.
2. Materials and Methods
We conducted a narrative literature review and search using the PubMed database with predefined
keywords, as well as MeSH terms. The literature search was finalized in March 2020. The search
strategy included the terms: (omega-3 fatty acids OR n-3 fatty acids OR fish oil) AND (sport OR sports
OR performance). The selection criteria were randomized controlled clinical trials that were published
between January 2010 and February 2020. The search was limited to humans, and the English language.
Initially, 310 articles were retrieved. After screening of titles and abstracts, 52 papers were selected for
further examination. In addition, 1 article was identified by subsequent hand search, so that 53 articles
reporting on randomized controlled trials over the last decade in both athletes as well as amateurs
were included in this narrative review. We wanted to explore whether the dose or duration of the
supplementation was influencing the findings. However, these factors were not normally distributed
across the studies so we decided to adopt a simple dichotomized approach to enable us to compare the
highest against the lowest for both dose and duration [15].
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3. Results
EPA and DHA can affect many aspects of human physiology/metabolism and these can
subsequently impact outcomes related to sporting performance, recovery and illness/injury is shown
in Figure 1.
Figure 1. Areas of interest for supplementation with eicosapentanoic acid/docosahexanoic acid
(EPA/DHA) in sport nutrition in athletes as well as amateurs.
Of all the studies that were identified for this review, multiple outcomes were often reported
within each study, which in some cases made allocation to only one of the main topics a challenge
(performance, recovery or illness/injury). Hence the allocation of studies to performance, recovery or
illness was based on evaluation of the main outcome reported. Overall, of the 53 articles, 21 articles
reported on athletes and 32 in amateurs.
3.1. The Influence of Dose and Study Duration in Athletes and Amateurs on Performance
Thirty studies were identified that assessed the effects of EPA/DHA supplementation with a
focus on performance-related outcomes in athletes and amateurs (Table 1). One study was used twice
because of 2 sets of data (low dose and high dose groups). Ten of those studies were conducted in
athletes, with 21 in amateurs. The amounts used in the studies reviewed here vary for EPA from 0.06
g to 4.9 g per day and for DHA from 0.04 to 4.7 g DHA per day. The duration of supplementation
ranged from acute to 24 weeks.
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Table 1. Effects of EPA/DHA supplementation with a focus on performance-related outcomes in athletes and amateurs.
Population (n)
Sex
Age ± SD (Years) *
Duration




23.2 ± 1.2 and 27.1 ± 2.7
8 w 0.8 g EPA2.4 g DHA
Oxygen peak consumption (VO2 peak)
Sustained submaximal exercise tests at 55%
of peak workload
Heart rate (HR), including peak heart rate
during incremental workloads to exhaustion,
reduced
Steady-state submaximal exercise HR, reduced
Whole body O2 consumption, reduced
HR pressure product, reduced
VO2 peak, no difference




24.1 ± 2.4 and 26.9 ± 2.8
6 w 2.0 g EPA0.4 g DHA 10-km time trials
10-km time trial performance, no difference
Exercise-induced increases in plasma cytokines,
myeloperoxidase, blood total leukocytes, serum
C-reactive protein (CRP), and creatine kinase
(CK); or the decrease in the salivary Immune





5 w 1.1 g EPA1.1 g DHA
Pre-season training
Muscle soreness countermovement jump







21.7 ± 1.0 and 23.2 ± 1.1
5 w 1.9 g EPA + DHA
Endurance performance, Recovery
Resting blood pressure (BP)
Fasting serum triglycerides (TG) HR during
treadmill running at 10 km/h
TG, decreased
Diastolic blood pressure, decreased
HR during submaximal exercise, decreased




24.5 ± 5.0 4 w
4.9 g EPA

















NO concentration (∆NO), increased
Positive correlation between baseline
post-intervention NO concentration and
VO2 max (r = 0.72; p < 0.01)
Positive correlation between ∆NO and ∆VO2max








Endurance test (bicycle time trial of approx.
1 h)
Red blood cells (RBC) characteristics and
lipid peroxidation
RBC characteristics, no difference
Exercise performance, no difference
Rate of LDL oxidation, decreased
The amount of dienes, no difference
Effects of exercise, no difference
[22]




Age ± SD (Years) *
Duration
(Weeks) Dose EPA/DHA (g/d) Exercise Intervention/Test Effects of EPA/DHA Compared to Control Reference
Cyclists (26)
M
24 ± 7 and 23 ± 5 8 w
0.56 g DHA
0.14 g EPA
O2 consumption and fatigue
Isometric quadriceps strength
Power output of maximal 6 s cycle sprinting,
unchanged
Power output during 5 min time trail (TT),
unchanged
Maximal voluntary contraction, unchanged








Group 1: 0.75 g EPA, 0.05 g
DHA per 10 kg body weight
Group 2: 0.15 g EPA, 0.1 g
DHA per 10 kg body weight
Recovery strategy following 100 plyometric
drop jumps
Squat jump performance, increased in group1
CMJ performance, unchanged






67.5 ± 0.4 24 w
n-6/n-3 polyunsaturated fatty
acids (PUFA) ratio below 2 Resistance training
Isometric strength performance, no difference
Dynamic peak power and time to reach peak
power (i.e., shorter time) during knee extension,
increased








Age-associated loss of muscle mass and
function
Thigh muscle volume, handgrip strength,
one-repetition maximum (1-RM) lower- and
upper-body strength, and average power
during isokinetic leg exercises
Thigh muscle volume, increased
Handgrip strength, increased
1-RM muscle strength, increased




64 ± 1.4 21 w 3 d
0.4 g EPA
0.3 g DHA Muscle strength and functional capacity
The peak torque and rate of torque development
for all muscles, increased
The activation level and electromechanical delay









Training-induced increases in muscle mass
and function
Maximal isometric torque increased after
exercise training in females, but not in men.
Maximal isokinetic torque at 30, 90, and 240◦
s−1, 4-m walk time, chair-rise time, muscle
anatomic cross-sectional area, and muscle fat, no
difference
Muscle quality in females after exercise training
increased no differences in males.
No differences in glucose, insulin, or
inflammatory markers
[28]




Age ± SD (Years) *
Duration
(Weeks) Dose EPA/DHA (g/d) Exercise Intervention/Test Effects of EPA/DHA Compared to Control Reference




12 w 0.66 g EPA0.44 g DHA
Muscle strength
Physical performance
Muscle strength, no difference






Moderate physical activity (3 d/week for 45
min), at 75 % of age-predicted maximal HR.




HR at rest, reduced
HR during submaximal exercise, reduced [30]
Healthy (19)
M
24 ± 0 and 21 ± 0 years
8 w 3.5 g EPA,0.9 g DHA
Resistance exercise
Skeletal muscle biopsies were obtained
before and after supplementation for
assessment of muscle lipid composition and
protein kinase activities.
Muscle protein synthesis, no difference
Protein kinase B (PKB) activity at rest, reduced






8 w 0.91 g EPA0.4 g DHA Maximal O2 uptake and oxygen uptakeduring submaximal exercise
Negative linear correlation in change between
erythrocyte EPA and whole O2 uptake during










Changes in maximal voluntary isometric
contraction torque
Range of motion
Upper arm circumference, Delayed onset
muscle soreness (DOMS).
M-wave latency,
Maximal voluntary contraction (MVC) torque,
higher






8 w 0.6 g EPA0.26 g DHA
Eccentric contraction-induced muscle
damage
Changes in the MVC torque
ROM
Upper arm circumference, muscle soreness
CK, myoglobin, interleukin-6 (IL-6), and
tumor necrosis factor a (TNF-α) levels
MVC 2–5 days after exercise, increased
ROM at 1–5 days after exercise, increased
Muscle soreness 3 days after exercise, reduced





8 w 0.56 g DHA0.14 g EPA
HR, HR variability and HR recovery during
rest, intense exercise and recovery
The mean HR during supine resting conditions,
no difference
HR variability at rest, decreasing trend
Peak HR, no difference
HR during submaximal exercise, decreased
Supine HR recovery (half-time) after cycling,
faster
[35]




Age ± SD (Years) *
Duration




8 w 1.9 g EPA1.5 g DHA
Hyperinsulinemic-hyperaminoacidemic
clamp





8 w 1.9 g EPA1.5 g DHA
Hyperinsulinemic-hyperaminoacidemic
clamp





8 w 0,6 g EPA0.3 g DHA Aerobic exercise VO2max, increased [38]
Healthy (68)
M and F





DOMS, extension and torque
Quality of life
Pain following eccentric exercise, reduced
Extension or strength, no difference
Blood lactate, lower
Emotional stability, improved





3 w 5 d 0.06 g EPA0.04 g DHA
Muscle damaging exercise (downhill
running)
Strength loss (MVC), reduced
skeletal troponin (sTnI) and TNF-α at 2, 24, 48,
72 and 96 h., Mb at 24, 48, 72, 96 h., reduced
CK-MM at all-time, reduced
DOMS at 72 and 96 h, reduced
Protective effect against joint ROM loss at 96 h
Pain, reduced





3 w 0.38 g EPA0.51 g DHA
17 h training/week
Maximal voluntary isometric contractions
Wingate test
250 kJ time trial
Vastus lateralis, increased
Maximal voluntary isometric contractions, no
difference
Wingate percent power drop, reduced




24.1 ± 3.6 and 24.4 ± 2.6
2 w 0.38 g EPA0.51 g DHA
Sprint interval training with pre- and
post-training TT
Resting twitches, quadriceps MVC force, and
potentiated twitch force
Maximal voluntary, no difference




2 w 1.1 g EPA,0.7 g DHA
VO2max,
30 min cycling
Substrate oxidation, no change
Energy expenditure, no change
Energy efficiency, no change [43]




Age ± SD (Years) *
Duration
(Weeks) Dose EPA/DHA (g/d) Exercise Intervention/Test Effects of EPA/DHA Compared to Control Reference
Healthy (17)
F
22.5 ± 1.8 and 24.7 ± 3.6
1 w 6 g FO (5:1 EPA:DHA)
Post resistance exercise muscle soreness
Soreness during functional movements and
limb circumferences
Resistance exercise-induced static and functional
soreness responses, reduced
Static and functional muscle soreness, no
difference







50 g high-fat meal (4.7 g EPA)
50 g high-fat meal (4.7 g
DHA)
Exercise stress testing
Cardiac output, Blood pressure and systemic
vascular resistance (SVR)
SVR was lower at 5 h and during exercise
following the DHA but not EPA meal
Resting cardiac output, no difference
8-iso-PGF2α, no difference
Cardiac output during exercise, no difference
[45]
The order of articles is first on athletes then amateurs. Next, they are ordered by supplement duration. M = male, F = female, w = week, d = day, g = gram (numbers are rounded from
three to two decimals). * were provided, first for the intervention group, secondly for the placebo group.
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A recent study in 26 competitive soccer players supplemented with 4.9 g EPA and 1.4 g DHA
per day over 4 weeks found that the increases in leg strength, sprint speed, explosive power and
anaerobic endurance were not different between groups [20]. No benefits of supplementation with
0.56 g EPA and 0.14 g DHA over 8 weeks were found on power output and MVC in a group of trained
males [23]. In contrast, explosive power, fatigue and muscle soreness were improved in athletes
consuming 1.1 g of each EPA and DHA over 5 weeks [23]. Similarly, in a study with trained males,
squat jump performance was improved after a single acute supplementation with 0.75 g EPA and
0.05 g DHA [24]. A greater number of studies have been conducted in amateurs. Muscle strength
was increased in long-term supplementation studies with 0.4 g EPA and 0.3 g DHA over 21 weeks, or
1.86 g EPA and 1.5 g DHA over 24 weeks [26,27]. Mixed results were reported from studies in amateur
males with 0.375 g EPA and 0.51 g DHA [41,42] where the latter reported no benefits on strength but
improved fatigue. A short-term supplementation with 2 g EPA and 1 g DHA over one week did
not demonstrate any effects on arm circumference or volume [46]. No improvement in strength was
found in amateur males and females after 4 weeks of 2.7 g fish oil [39]. Muscle protein synthesis, was
unchanged after 3.5 g EPA and 0.9 g DHA over 8 weeks [31].
Anaerobic endurance improved after supplementation with 4.9 g EPA and 1.4 g DHA over 4
weeks in a group of soccer players [20]. Others reported beneficial results in male athletes in various
parameters relevant for endurance such as submaximal exercise HR and O2 consumption VO2max
and relative O2 consumption [16,23] (Table 1). Others found diastolic blood pressure and HR during
submaximal exercise decreased in athletes, supplemented with 1.9 g EPA/DHA, but these changes did
not translate in delayed time to exhaustion during a run, nor to enhanced recovery [19]. While the
above changes could result in enhanced performance, the time to voluntary fatigue was not different
between groups in a comparable study [16]. Nor did athletes exercising during a 1-h time trial [22]
or a 10-km time trial [17] show a beneficial effect of supplementation with EPA/DHA. In amateur
males, no effects on cardiac output at rest or during an exercise stress test were found after acute
supplementation with either 4.7 g EPA or 4.7 g DHA, but systemic vascular resistance was reduced
following DHA supplementation only [45]. An earlier study found neither substrate oxidation, energy
expenditure nor energy efficiency to be affected by 2-week supplementation with 1.1 g EPA and 0.7 g
DHA in amateurs [43]. However, a study in amateurs in which EPA/DHA were administered in doses
of 0.6 g and 0.3 over 8 weeks, led to a significant increased VO2max [38]. An improved O2 uptake
during submaximal exercise in amateurs after supplementation with 0.9 g EPA and 0.4 g DHA was
confirmed by others [30,32]. The latter study was based on cardiovascular parameters in response
to submaximal exercise with amateur overweight adults [30]. Similarly, amateurs who had received
0.8 g EPA and 2.4 g DHA over 8 weeks showed significantly lower heart rates during incremental
work load up to exhaustion, lowered steady-state submaximal exercise heart rates and increased whole
body O2 consumption [16]. Also smaller amounts (0.56 g DHA and 0.14 g EPA) tended to reduce
mean exercise HR and improved HR recovery in amateurs [35]. The influence of study duration on
performance-related outcomes is depicted in Figure 2.
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Figure 2. Impact of trial duration on performance-related outcomes in athletes and amateurs by
dichotomous split.
Using a cut-off of 5 weeks for athletes and 8 weeks for amateurs gives a dichotomous split.
The evidence favors longer trials which is more pronounced in amateurs.
Using a dichotomous split for each, athletes and amateurs, the cut-off points were 5 weeks and 8
weeks respectively. For athletes, 4 out of 5 studies and 13 out of 14 studies in amateurs, favored the
longer duration studies in terms of providing positive performance outcomes (Figure 3).
Figure 3. Impact of dose on recovery-related outcomes in athletes and amateurs by dichotomous split.
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Using a cut-off of 2 d/day for athletes and 1.8 g/day for amateurs gives a dichotomous split.
The evidence favors the higher doses which is more pronounced in amateurs. However, even the
lower dose gives more positive changes as opposite to the low dose in athletes.
The data in amateurs were more pronounced. The cut-off points for the dose were 2 g/day for
athletes and 1.8 g/day for amateurs. The data suggest that doses below 2 g/day in athletes sometimes
induce a beneficial outcome, while above that cut-off point 4 out of 5 studies showed beneficial
outcomes. The dose in amateurs appear to be of less influence, as 18 out of 21 studies reported a
beneficial outcome regardless whether above or below the cut-off point.
3.2. The Influence of Dose and Study Duration in Athletes and Amateurs on Recovery
Twenty-two studies were identified that assessed the effects of EPA/DHA supplementation with a
focus on recovery-related outcomes in athletes and amateurs Table 2.
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Table 2. Effects of EPA/DHA supplementation with a focus on recovery-related outcomes in athletes and amateurs.
Population (n)
Sex
Age ± SD (Years) *




18.9 ± 0.5 8 w 1.14 g DHA
Mitochondria dynamics and antioxidant status
in peripheral blood mononuclear cells (PBMC)
PBMCs, Mn-superoxide dismutase protein levels,
and their capability to produce reactive oxygen
species, no difference
Proteins related to mitochondrial dynamics,
increased
The content in mitofusins (Mtf)-1 and Mtf-2, optic
atrophy protein-1 (Opa-1), and mitochondrial
transcription factor A (Tfam), increased
Cytochrome c oxidase (COX-IV) activity and
uncoupling proteins (uncoupling protein) UCP-2




20.4 ± 0.5 and 19.3 ± 0.4 8 w 1.14 g DHA
Pro-oxidant and antioxidant status of peripheral
blood mononuclear cells (PBMC)s during
training and acute exercise
UCP3 levels after training, increased
Superoxide dismutase protein levels after acute
exercise, increased





19.7 ± 0.4 8 w 1.16 g DHA
Eicosanoids levels and PBMCs eicosanoids
production
Training:
Cyclooxygenase 2 (COX-2) protein levels, no
difference




prostaglandin E (PGE)1 and PGE2 production,
decreased
Expression of NFκβ, COX-2, 15-LOX2, 5-LOX, or




20.4 ± 0.5 and 19.3 ± 0.4 8 w 1.16 g DHA
Cytokine production, by LPS-stimulated PBMCs
after exercise
Exercise-induced increase in IL6, IL8, vascular
endothelial growth factor
, INFγ, TNFα, IL1α, IL1β, MCP1, decreased





19.7 ± 0.4 8 w 1.14 g DHA
Plasma oxidative balance and anti-inflammatory
markers after training and acute exercise
Biomarkers for oxidative balance in plasma, no
difference
During training, plasma protein markers of
oxidative damage, haemolysis degree, antioxidant
enzyme activities, increased
Lipid oxidative damage, no difference
PGE2 in plasma after acute exercise, increased
[51]




Age ± SD (Years) *
Duration (Weeks) Dose EPA/DHA (g/d) Exercise Intervention/Test Findings Reference
Football players (15)
M
20.4 ± 0.5 and 19.3 ± 0.4 8 w 1.14 g DHA
After training and acute exercise
Oxidative balance
Oxidative damage markers
Activity and protein level of antioxidant
enzymes
Enzyme activities in erythrocytes, increased
Catalytic activity of superoxide dismutase,
increased





22.8 ± 1.4 and 22.3 ± 1.4 6 w
0.6 g EPA
0.4 g DHA Oxidative stress at rest and after training
Triglycerides, reduced
Resting MDA concentrations, increased
NO and oxidative stress, i.e., malondialdehyde
(MDA), maximum rate of oxidation (Rmax),
conjugated dienes (CD)max, and NO), increased








Physiological markers of recovery measured
over three days following eccentric exercise
Muscle soreness, reduced compared to protein
Blood concentrations of CK, reduced compared to
CHO





45.6 ± 1.6 and 22.8 ± 3.8 5 w
0.82 g DHA +
0.33 g α-tocopherol Maximal exercise test
Oxidative and nitrative damage, no change





45.6 ± 1.6 and 22.8 ± 3.8 5 w
0.82 g DHA +
0.33 g α-tocopherol Acute exercise test




23.1 ± 1 and 23.6 ± 1.9
4 w 1.2 g DHA [56]2.4 g EPA During intense exercise
Production of tumor necrosis factor (TNF)-α,
decreased
Interleukin (IL)-1β, decreased
Production of IL-6, increased
Production of interferon (IFN)-γ, decreased






8 w 1.8 g FO
Eccentric exercise
Knee ROM, perceived pain, and thigh
circumference of the right leg
Pain and ROM before, immediately, and 24 h after
the exercise, no difference


















Age ± SD (Years) *
Duration (Weeks) Dose EPA/DHA (g/d) Exercise Intervention/Test Findings Reference
Healthy (24)
M
21.0 ± 0.9 and 20.7 ± 1.1 6 w 1.3 g FO
1 h of exercise with a constant work load
corresponding to 60% of their individual
VO2max) followed by a maximal rate
Blood antioxidant status and lipid profile
Resting concentration of triglycerides, decreased
Superoxide dismutase activity, improved





24 ± 3.8 6 w
1.3 g EPA
0.3 g DHA
Single bout of exercise, maximal exercise test
and a 1-h bout of endurance exercise at 70% VO2
peak
Plasma IL-6, EPA, DHA and cortisol; PBMC IL-2,
IL-4 and interferone (IFN)-γ production;
neutrophil phagocytosis/oxidative burst; and
natural killer (NK) cell cytotoxic activity
At 3 h post-exercise PBMC, IL-2 and NK cell
activity increased
PBMC, IL-4 and IFN-γ productions, plasma IL-6





23 ± 2.3 6 w
1.3 g EPA
0.3 g DHA
Exercise-induced markers of oxidative stress
and muscle damage
Eccentric strength exercise
CK, protein carbonyls, endogenous DNA damage,
muscle soreness or MVC, unchanged
Plasma thiobarbituric acid reactive substances,
decreased





25.8 ± 5.3 6 w
0.24 g EPA
0.12 g DHA
Maximal incremental exercise test and cycling
TT.
Post-exercise immune function and performance
Plasma IL-6 and thiobarbituric acid reactive
substances (TBARS) concentrations and,
erythrocyte fatty acid composition
NK cell cytotoxic activity and PBMC IL-2, IL-4,
IL-10, IL-17 IFNγ production
PBMC IL-2 and NK cell cytotoxic activity 3 h
post-exercise, increased
Plasma IL-6 and TBARS, PBMC IL-4, IL-10, IL-17
and IFNγ production, along with performance





22.0 ± 2 3 w 5 d
0.06 g EPA
0.04 g DHA
Muscle damaging exercise (downhill running)
sTnI and TNF-α at 2, 24, 48, 72 and 96 h., Mb at 24,
48, 72, 96 h., reduced
CK-MM at all-time, reduced
DOMS at 72 and 96 h, reduced
MVC, reduced






33.3 ± 2.4 and 31.9 ± 3.1
1 w 2 d 3 g DHA Eccentric strength exercise
Increase in soreness was 23% less
Number of participants who were able to achieve
full active elbow extension 48 h after eccentric
exercise was greater in the DHA group
No differences for passive elbow extension or arm
swelling
[63]




Age ± SD (Years) *









Arm circumference and volume
Temperature
Soreness, decreased
Arm circumference, no difference
Arm volume, no difference




22.5 ± 1.8 and 24.7 ± 3.6 1 w 6 g FO (5:1 EPA:DHA)
Post resistance exercise muscle soreness
Soreness during functional movements and limb
circumferences
Muscle soreness, no difference [44]
Healthy (45)
M
29.3 ± 6.2 and 31.1 ± 4.9 Acute 1.8 g FO
Plasma levels of PGE2, IL-6, TNF-α, CK, LDH,
and myoglobin (Mb) after eccentric exercise
TNF-α and PGE2 immediately, 24, and 48 h after
exercise, reduced
Elevation concentration of IL-6, CK, and Mb at 24
and 48 h after exercise, reduced
Plasma concentration of LDH immediately, 24,
and 48 h after the exercise program, reduced
[64]
The order of articles is first on athletes then amateurs. Next they are ordered by supplement duration. M = male, F = female, w = week, d = day, g = gram (numbers are rounded from three
to two decimals).*were provided, first for the intervention group, secondly for the placebo group.
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Eleven of those studies were conducted in athletes, 11 in amateurs. The amounts used in the
studies reviewed here varied for EPA from 0.06 g to 2.4 g per day and for DHA from 0.04 to 1.2 g DHA
per day. The duration of supplementation ranged from acute to 24 weeks (Table 2).
A recent study in 30 male athletes found that 6 weeks of supplementation with 0.55 g EPA
and 0.55 g DHA reduced muscle soreness after eccentric exercise, without an effect on muscle
function [54]. Reduced soreness in amateurs due to supplementation with EPA/DHA has been
consistently reported [34,40,46]. Soreness following eccentric exercise was also reported less in
amateurs who received 3 g of DHA for a little more than a week [63]. Furthermore, delayed onset of
muscle soreness was also reported after 8 weeks of 0.6 g EPA and 0.26 g DHA [33], or 4 weeks of 2.7 g
of fish oil [39]. An intervention study in 27 amateur males showed no effect of 1.8 g/d omega-3 fatty
acids on knee ROM, perceived pain, and thigh circumference when measured immediately, and after
24 h of eccentric exercise [58]. However, perceived pain and ROM were improved at 48 h post-exercise.
In contrast, participants who were able to achieve full elbow extension improved after 1 week of
supplementation with 3 g DHA, while passive extension or arm swelling were not [63]. Others found
a trend for reduced soreness after eccentric exercise in amateur females [44].
In young, but not older athletes, pro-inflammatory gene expression in response to exercise
were increased following 5 weeks supplementation with 0.83 g DHA, in combination with
alpha-tocopherol [55]. In contrast, decreased inflammatory responses following intense exercise were
reported in a group of athletes that received doses of 1.2 g EPA and 2.4 g DHA [57]. Partially beneficial
results were reported after 1.16 g DHA for 8 weeks by exerting anti-inflammatory effects via increasing
plasma PGE2 [49]. Furthermore, exercise-induced increases in various cytokines, including interleukin
6 and 8, were decreased following supplementation with 1.16 g DHA for 8 weeks [50], while one study
found interleukin 4 and 6 remained unaffected in amateurs that received 1.3 g EPA and 0.3 g DHA for
6 weeks [60].
In athletes, improved antioxidant capabilities in response to acute exercise were reported after
supplementation with 1.14 g of DHA over 8 weeks [48]. A slightly higher dose of DHA over a
longer period of time decreased exercise-induced peroxidative damage [52]. However, using the
same supplementation protocol, the authors showed increased markers of oxidative damage during
training [51]. Potentially aggravating effects were also reported in athletes with increased oxidative
stress at rest and after training following the consumption of 0.6 g EPA and 0.4 g DHA [65]. In a
further study, 0.82 g of DHA in combination with 0.33 g alpha-tocopherol showed neither an effect on
oxidative damage following a maximal exercise test nor changes in the antioxidant gene expression [55].
In amateurs, 1.3 g EPA and 0.3 g DHA reduced certain markers of oxidative stress after a single bout
of exercise, while other parameters, including endogenous DNA damage and muscle soreness, were
unaffected [61]. Regarding study duration the cut-off points were 8 weeks for athletes and 6 weeks for
amateurs (Figure 4).
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Figure 4. Impact of trial duration on recovery in athletes and amateurs by dichotomous split.
Using a cut-off of 8 weeks for athletes and 6 weeks for amateurs gives a dichotomous split.
The evidence favors longer trials in athletes and amateurs.
Studies of less than 8 weeks duration in athletes showed no clear picture of the benefits of omega-3
fatty acids, only 2 out of 5 studies reported beneficial outcomes. However, 6 out of 6 studies with more
than 8 weeks reported positive changes due to the EPA/DHA supplementations. Studies in amateurs
showed positive changes of the omega-3 fatty acids in 4 out of 5 studies below 6 weeks of duration
and 6 out of 6 studies of more than 6 weeks duration. Applying the dichotomous approach on the
dose, the observed cut-off points for athletes and amateurs were 1.14 g/day and 1.8 g/day, respectively.
One out of 4 studies reported beneficial effects of the EPA/DHA supplementation in athletes when
the supplementation was lower than 1.14 g/day. However, all studies with a dose above 1.14 g/day
showed beneficial effects. In amateurs, 10 out of 11 studies showed beneficial effects of EPA/DHA
supplementation on recovery-related outcomes (Figure 5).
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Figure 5. Impact of dose on recovery in athletes and amateurs by dichotomous split.
Using a cut-off of 1.14 g/day for athletes and 1.8 g/day for amateurs gives a dichotomous split.
Overall, the data are clearer for amateurs. The evidence favors higher doses in athletes and amateurs.
Overall, the evidence shows that EPA/DHA have the potential to decrease the production of
inflammatory eicosanoids, cytokines, and ROS. Amateurs appear to benefit more; particularly soreness
is beneficially affected by supplementation with EPA/DHA (Table 2).
3.3. Reduced Risk of Injury/Illness
Four studies were identified that assessed the effects of EPA/DHA on injury/illness (Table 3).
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Table 3. Effects of EPA/DHA supplementation with a focus on injury/illness-related outcomes in athletes and amateurs.
Population (n)
Sex
Age ± SD (Years) *





Over the course of a season 2, 4, or 6 g of DHA NeuroprotectionNeurofilament light (NFL)
DHA likely attenuated serum NFL coincident with
increases in serum NFL by likely small and













The peak fall in forced expiratory volume (FEV)1
was similarly reduced in both intervention groups
compared to placebo (p < 0·001).
Baseline fraction of exhaled NO was reduced by 24
% (p = 0·020) and 31 % (p = 0·018) after 6·2 and 3·1
g/d n-3 omega-3, respectively.
Peak increases in 9α, 11β PGF2 after EVH were
reduced by 65 % (p = 0·009) and 56 % (p = 0·041)






3 w 0.07 g EPA 0.05 g DHA EVH challenge
Maximum fall in post-EVH FEV1 significantly
reduced (p < 0.05)
Pre- and post- EVH, EBC ph cyst-LT and
8-isoprostane, and urinary 9a, 11b-PGF2 and CC16
concentrations were significantly reduced (p <
0.05)exhaled breath condensate pH (EBC pH) and
asthma symptom scores were significantly
improved (p < 0.05)










No changes in sputum eosinophils
No differences in Forced expiratory volume [69]
The order of articles is first on athletes then amateurs. Next they are ordered by supplement duration. M = male, F = female, w = week, d = day, g = gram (numbers are rounded from three
to two decimals). *were provided, first for the intervention group, secondly for the placebo group.
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Two of those studies report on athletes and two on amateurs. A study in trained males showed
similar improvements in markers of pulmonary function, albeit with a much higher dose of up to
3.7 g EPA and 2.5 g DHA over 3 weeks [67]. Improved markers for pulmonary function, including
hyperpnea-induced bronchoconstriction, a surrogate for exercise-induced bronchoconstriction (EIB),
were also observed after 3 weeks of a low daily dose of 0.07 g EPA and 0.05 g DHA during an eucapnic
hyperventilation challenge in amateurs [68], with EPA/DHA possibly acting as an inflammatory
antagonist. In contrast, no changes in inflammatory markers were found in a study in amateur males
and females with a high dose of 4 g EPA and 2 g DHA over 3 weeks [69].
Evidence from observational and intervention studies suggests a beneficial effect of EPA/DHA in
asthma in the general population [70–72]. An early intervention study in athletes showed that fish oil
supplementation reduced exercised-induced bronchoconstriction [73]. In professional football players,
a small to moderate neuroprotective effect of 2 g DHA per day over the course of an American football
season was reported [66].
4. Discussion
The evidence presented in the studies reviewed here show that EPA/DHA may have the potential
to influence not only the metabolic response of muscle to nutrition, but also the physiological functional
response to exercise and post-exercise conditions. However, these physiological and metabolic
adaptations do not always translate into improved performance.
Based on the review of the literature presented here, there seem to be bigger gains for amateurs.
It is possible that there is a genuine difference, that amateurs have more to gain from EPA/DHA
supplementation, but it could be due to the higher metabolic flux in athletes meaning they require more
EPA/DHA to see the benefits (either in terms of dosage or supplementation duration). Alternatively,
it could be the case that studies tend to be longer in the amateur groups (from experience, amateurs
are more willing to keep training constantly for longer than athletes), so the positive performance
gains are more likely to develop in the longer studies more often seen in amateurs. It should also
be acknowledged that the potential for performance gains is narrower in athletes due to the law of
diminishing returns.
4.1. Increased Performance
It is known that the response of skeletal muscle to exercise can be influenced by the nutritional
status of the muscle [74]. This effect is not confined to macronutrients, but EPA/DHA can also potentially
influence the exercise and nutritional response of skeletal muscle [75], this in turn can partly explain
the observed decrease in soreness. Although the potential for EPA/DHA supplementation to improve
muscle mass or function, is supported by mechanistic explanations including structural changes of
the muscle cell membranes [76,77] this review found no consistent effect on strength in amateurs.
Muscle protein synthesis, a fundamental process in muscle growth, was unchanged after 3.5 g EPA
and 0.9 g DHA over 8 weeks, although muscle biopsies revealed that kinase signaling in response
to resistance training was altered [31]. However, it has been shown that incorporation of EPA/DHA
in muscle cells stimulates foal adhesion kinase, which regulates MPS [78], and may actually have
a beneficial effect on muscle protein synthesis. This was shown in amateur females and males in
response to anabolic stimuli, in two 8-week intervention studies with 1.86 g EPA and 1.5 g DHA [36,37].
Interestingly, selective improvement in muscle torque and muscle quality after, but not during, exercise
was reported in females only [28]. EPA and DHA seemed to optimize the effects of resistance training
in amateur elderly females, including dynamic and explosive strength, however these effects did not
result in an overall improvement of isometric strength performance [25]. These data corroborate other
reports that possibly older adult populations may benefit from EPA/DHA supplementation in the
context of preserving muscle mass in an older population [14].
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Peroxisome proliferator-activated receptor-gamma coactivator (PGC-1a) is a key regulator of
mitochondrial biogenesis. In obese participants, EPA has been shown to stimulate mitochondrial
biogenesis [79], which could result in improved endurance regulated via the PGC-1a pathway. It can
be hypothesized that lower heart rates and improved O2 uptake may lead to better O2 delivery
to contracting muscles, thereby enhancing endurance performance [80]. Another mechanism for
improved endurance could be that EPA/DHA increase the deformability of RBC, which in turn could
increase oxygen delivery to the muscles [81]. It has also been shown that exposure of human myotubes
to EPA upregulated specific genes that regulate beta-oxidation [82]. Moreover, clinical evidence
suggests that EPA/DHA increase fatty acid oxidation via the carnitine palmitoyltransferase-II [38,83].
These mechanisms may well have contributed to the increased fat oxidation during rest by 19% and
during exercise by 27% following supplementation of 3 g/day EPA/DHA over 12 weeks in female
adults [84].
4.2. Enhanced Recovery
The concept of muscle damage following intense eccentric exercise is accepted [85]. The acute
exercise recovery period is defined as the initial 96 h following exercise [86]. EPA and DHA have
been described to increase the structural integrity of muscle cell membranes [77], which in turn may
explain the protective effect of EPA/DHA. This has recently been demonstrated in soccer players
where 1.1 g/day EPA/DHA combined with 30 g/day whey protein resulted in reduced levels of muscle
soreness along with a reduction of plasma CK concentration [54]. Furthermore, exercise-induced
muscle damage causes responses that include DOMS and muscle fatigue. It also leads to increased
circulating neutrophils and interleukin-1 peaking within 24 h after the exercise, with skeletal muscle
levels remaining elevated for 48 h and longer [87]. Inflammation is a key process in muscular repair
and regeneration, the potential of EPA/DHA to accelerate the recovery process via immune modulation
come into play. EPA/DHA influence immune modulation via increasing interleukin 2 (IL2) [60,62],
where an acute dose of fish oil improved markers of inflammation after eccentric exercise in amateur
males [64]. The authors found that in 45 amateur males an acute dose of 1.8 g fish oil before a
single eccentric exercise bout lead to a smaller exercise-induced elevation in tumor necrosis factor-α
(TNF-α) and prostaglandin (PG)E2 immediately, 24 h, and 48 h after exercise, as well as significantly
lower elevation in the concentrations of interleukin 6 (IL-6), CK, and myoglobin (Mb) at 24 and 48 h
after exercise.
Furthermore, in theory EPA/DHA may contribute to insulin-sensitizing effects because EPA
and DHA are natural ligands for peroxisome proliferator-activated receptor γ (PPARγ); following
activation of PPARγ, nuclear factor kappa B (NF-κB) activity is suppressed, reducing the release
of pro-inflammatory cytokines [88]. At a cellular level, fatty acids have an important function in
regulating the activity of certain enzymes and by acting as signaling molecules [3]. It has been shown
that 1.3 g fish oil consumption over 6 weeks has the potential to ameliorate the exercise-induced
decrease in superoxide dismutase activity in sedentary control participants [59]. In the same study, fish
oil tended to increase the catalase activity after 1 h of recovery. Together, these findings suggest that
EPA/DHA may activate the superoxide dismutase and catalase pathways. Oxidative stress is usually
defined by an increased formation of prooxidants and decrease of antioxidants. This disturbance can
lead to oxidative damage to cellular components such as lipids, protein and DNA. However, oxidative
stress and inflammation are interdependent. Inflammation can develop following oxidative stress, on
the other hand inflammation can induce oxidative stress which further enhances inflammation [89].
Exercise mode, intensity, and duration, as well as the subject population tested, can impact the extent
of oxidative stress. Furthermore, the use of antioxidant supplements such as EPA/DHA can impact
the outcomes. EPA and DHA have been shown to improve muscle function in older adults [26,27].
A recent paper supports the view that EPA/DHA could bring benefits by attenuating the generation of
oxidative stress [90]. In this review, preliminary evidence is provided that EPA/DHA may be beneficial
in counteracting exercise-induced inflammation. However, current data are inconclusive as to whether
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EPA/DHA supplementation at the reported dosages is effective in attenuating the immune-modulatory
response to exercise and ultimately improve recovery.
4.3. Reduced Risk of Injury/Illness
Optimal sports performance requires optimal health. EIB is a prominent asthma phenotype
affecting an estimated 90% of asthma patients and up to 50% of elite athletes [91]. Reduced inflammation
ameliorates the severity of asthma and exerts a bronchodilatory effect. The anti-inflammatory effects
of EPA/DHA may be linked to a change in cell membrane composition and lipid mediators such
as resolvins [92]. Alternatively, the effect may also be mediated by the decreased production of
bronchoconstrictive leukotrienes [93].
Certain sports like soccer or rugby can lead to traumatic brain injuries (TBI). As outlined
by others, the number of sport-related concussions are increasing globally [94]. Although DHA
and EPA have shown promising in vitro and animal evidence of neuronal repair capacities in
TBI [95], there has been only one large, controlled intervention study conducted in American football
players. The underlying mechanisms for this observation have not been completely elucidated
but it is suggested that saturation of brain cells with DHA in particular may facilitate healing
after brain trauma, thereby counteracting negative long-term results [96]. Other mechanisms by
which specifically DHA could convey neuroprotection include preservation of myelin, alleviation
of glutamate cytotoxicity, suppression of mitochondrial dysfunction and down-regulation of
alpha-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptor sub- units. Details are discussed
elsewhere [94].
This review provides a new angle on the evidence linking EPA/DHA with performance and
recovery-related outcomes by analyzing basics in study designs in the context of the training status.
The limitations of this analysis include its exploratory nature. The background diet is hardly considered
in the studies that were analyzed; therefore, a fundamental confounder cannot be included in this
analysis. Other aspects like the sex of study participants were not considered, due to the limited
number of studies. Also, the questions of responders vs. non-responders remains unanswered, and all
of these aspects need to be addressed in future clinical trials. It cannot be highlighted enough to pay
utmost attention to the actual dose and duration when designing clinical trials. Dichotomization is
often used in statistical applications to identify thresholds of continuous variables. A recent simulation
study suggests that common methods of dichotomization theoretically discover the true threshold [97]
albeit with higher numbers of subjects than we had in our review. For the purpose of this review we did
not apply subsequent statistical tests but confined ourselves to a descriptive use of dichotomization.
5. Conclusions
This review identified evidence to support a role of EPA/DHA in improved performance
such as enhanced endurance, markers of functional response to exercise, enhanced recovery or
neuroprotection. The majority of evidence stems from studies in amateurs rather than athletes,
although most recommendations for EPA/DHA supplementation for improved performance are
made for athletes. In practical terms, athletes, and likely more so, amateurs may benefit from the
consumption/supplementation of EPA/DHA. The extent to which the different metabolic state, i.e.,
training status influences the response to the supplementations warrants further research. In general
terms there seems to be an effect of supplementation duration, with favorable outcomes appearing
more consistently after approximately 6–8 weeks. The same is true for EPA/DHA dosage, with better
responses from doses above approximately 1.5–2.0 g/day. Finally, it appears the beneficial outcomes
are more consistently seen in amateurs, so broadly speaking the amateurs might require lower doses
for a shorter period to experience gains.
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It remains to be investigated why the changes in markers do not always lead to measurable
improvements in clinical outcomes of performance, recovery and the reduced risk of illness/injury. In a
given, well-characterized population the quantity of EPA/DHA and the duration of the supplementation
play crucial roles and need to be well defined in order to clearly identify the effects of EPA/DHA
on performance. Also, certain questions remain to be investigated such as sex, responders vs.
non-responders, or if the habitual intake of EPA/DHA play a role in the efficacy of EPA/DHA for sports
nutrition. This exploratory analysis may, therefore, serve as guidance for the basic design of clinical
trials that investigate effects of EPA and DHA and avoid pitfalls of study durations that are too short,
optimal dose and most importantly the appropriate study population, as training status seems to be a
substantial aspect in determining the effects of EPA/DHA supplementation in sports nutrition.
Given that EPA/DHA are considered safe up to 5 g per day there seems little harm in recommending
EPA/DHA, even when further larger studies with optimal design are needed to confirm these
initial results.
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